Clinical Trial

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced Microsatellite Stable (MSS) colon cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-11-04; most recent amendment 2025-09-19.
Status change: Recruiting → Active, Not Recruiting 2025-09-19
Status change: Not Yet Recruiting → Recruiting 2023-11-09
Trial Details
NCT Number NCT06124378
Lead Sponsor First Affiliated Hospital of Guangxi Medical University
Conditions Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
Enrollment 60 participants
Start Date 2023-11-13
Primary Completion 2025-02-28 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-24